HOME2019-03-11T17:27:49+01:00

The PD-MitoQUANT Project

Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.

PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:

  • improve our understanding of mitochondrial dysfunction in Parkinson’s,

  • identify and validate molecular drivers and mechanisms in Parkinson’s, and

  • discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.

Latest News

Dr Ronald Melki, CNRS presents at World Parkinson Congress 2019

June 10th, 2019|

The 5th World Parkinson Congress (WPC) was held in Kyoto, Japan from June 4– 7, 2019. More than 3,000 people from more than 60 countries attended the meeting. At this meeting, Dr Ronald Melki of the Centre National de la Recherche Scientifique (CNRS) and PD-MitoQUANT PI presented: "What is alpha-synuclein- [...]

Parkinson’s UK blog celebrates their involvement in new two IMI projects

May 30th, 2019|

Beckie Port "From innovation to better treatments" is the title of a blog post published on 27 May 2019 by Dr Beckie Port. Beckie is Research Communications Manager at PD-MitoQUANT partner Parkinson's UK. This blog entry announces partnerships with two pan-European, IMI-funded research projects: PD-MitoQUANT and Neuronet. In [...]

PD-MitoQUANT PI Ronald Melki, CNRS delivers plenary lecture at AAN 2019 meeting

May 20th, 2019|

PD-MitoQUANT PI Ronald Melki of the Centre National de la Recherche Scientifique (CNRS) recently delivered the plenary lecture of the Frontiers in Neuroscience session of the American Academy of Neurology (AAN) annual meeting on May 8, 2019, in Philadelphia, USA. Through his talk, PD-MitoQUANT funding was acknowledged. The theme of the 71st [...]

Read more